Menu
No results found.
Weekly Share Price & Valuation Overview
Celltrion, Inc.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of various therapeutic proteins for the treatment of oncology diseases. It operates through Biopharmaceutical Medicines, Chemical Medicines, and Others segments. The company offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. It is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. In addition, the company engages in the wholesale/retail of medicines. The company distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
- Growth + profitability: double-digit revenue and profit margins.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- Revenue growth ≥10% indicates solid top-line momentum.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 39.62T
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 42.28T
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 3.66T
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 1.82T
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 983.58B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 16.50K
- Shares Outstanding
- 226.41M
- Float Shares
- 159.85M
- Implied Shares Outstanding
- 234.29M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
17.75%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
26.86%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
49.64%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
13.90%
- ROA Return on assets: net income ÷ total assets.
-
1.90%
- ROE Return on equity: net income ÷ shareholder equity.
-
2.95%
- Revenue Growth Strong Year-over-year revenue growth.
-
14.20%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
4.14%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
3.84%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.64
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.13
- Total Cash Cash and equivalents.
- KRW 970.72B
- Total Debt Short + long-term interest-bearing debt.
- KRW 2.23T
- Net Debt Total debt − cash (negative = net cash).
- KRW 1.26T
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.27
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW 978.30B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW 655.40B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
26.71%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
17.90%
- Cash Conversion (OpCF/EBITDA)
- 0.99
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.